Top 5 Stocks to Buy Now
→ Print this before your next trade (From Profits Run) (Ad)tc pixel Free JNJ Stock Alerts

Johnson & Johnson (JNJ) Competitors

Johnson & Johnson logo
$228.37 -0.02 (-0.01%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$228.54 +0.17 (+0.08%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

JNJ vs. MRNA, NVAX, ABBV, AZN, and BRK.B

Should you buy Johnson & Johnson stock or one of its competitors? MarketBeat compares Johnson & Johnson with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Johnson & Johnson include Moderna (MRNA), Novavax (NVAX), AbbVie (ABBV), Astrazeneca (AZN), and Berkshire Hathaway (BRK.B).

How does Johnson & Johnson compare to Moderna?

Johnson & Johnson (NYSE:JNJ) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Johnson & Johnson has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Johnson & Johnson has a net margin of 21.83% compared to Moderna's net margin of -143.55%. Johnson & Johnson's return on equity of 32.60% beat Moderna's return on equity.

Company Net Margins Return on Equity Return on Assets
Johnson & Johnson21.83% 32.60% 13.29%
Moderna -143.55%-26.64%-19.32%

In the previous week, Johnson & Johnson had 58 more articles in the media than Moderna. MarketBeat recorded 108 mentions for Johnson & Johnson and 50 mentions for Moderna. Johnson & Johnson's average media sentiment score of 1.36 beat Moderna's score of 0.46 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Johnson & Johnson
92 Very Positive mention(s)
8 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
3 Very Negative mention(s)
Positive
Moderna
23 Very Positive mention(s)
5 Positive mention(s)
8 Neutral mention(s)
12 Negative mention(s)
0 Very Negative mention(s)
Neutral

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Johnson & Johnson has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$94.19B5.84$26.80B$8.6526.40
Moderna$1.94B13.05-$2.82B-$8.15N/A

Johnson & Johnson presently has a consensus target price of $253.04, suggesting a potential upside of 10.81%. Moderna has a consensus target price of $36.60, suggesting a potential downside of 42.78%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, equities analysts plainly believe Johnson & Johnson is more favorable than Moderna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Johnson & Johnson
0 Sell rating(s)
7 Hold rating(s)
20 Buy rating(s)
0 Strong Buy rating(s)
2.74
Moderna
5 Sell rating(s)
11 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1.83

Summary

Johnson & Johnson beats Moderna on 12 of the 16 factors compared between the two stocks.

How does Johnson & Johnson compare to Novavax?

Novavax (NASDAQ:NVAX) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Johnson & Johnson has a net margin of 21.83% compared to Novavax's net margin of -14.73%. Johnson & Johnson's return on equity of 32.60% beat Novavax's return on equity.

Company Net Margins Return on Equity Return on Assets
Novavax-14.73% -14.82% 1.23%
Johnson & Johnson 21.83%32.60%13.29%

In the previous week, Johnson & Johnson had 103 more articles in the media than Novavax. MarketBeat recorded 108 mentions for Johnson & Johnson and 5 mentions for Novavax. Johnson & Johnson's average media sentiment score of 1.36 beat Novavax's score of 0.11 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novavax
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Johnson & Johnson
92 Very Positive mention(s)
8 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
3 Very Negative mention(s)
Positive

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novavax$1.12B1.34$440.30M-$0.58N/A
Johnson & Johnson$94.19B5.84$26.80B$8.6526.40

53.0% of Novavax shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Novavax currently has a consensus target price of $13.00, indicating a potential upside of 42.39%. Johnson & Johnson has a consensus target price of $253.04, indicating a potential upside of 10.81%. Given Novavax's higher possible upside, equities research analysts plainly believe Novavax is more favorable than Johnson & Johnson.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novavax
3 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.22
Johnson & Johnson
0 Sell rating(s)
7 Hold rating(s)
20 Buy rating(s)
0 Strong Buy rating(s)
2.74

Novavax has a beta of 2.45, indicating that its stock price is 145% more volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

Summary

Johnson & Johnson beats Novavax on 13 of the 16 factors compared between the two stocks.

How does Johnson & Johnson compare to AbbVie?

AbbVie (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Johnson & Johnson has a net margin of 21.83% compared to AbbVie's net margin of 5.79%. Johnson & Johnson's return on equity of 32.60% beat AbbVie's return on equity.

Company Net Margins Return on Equity Return on Assets
AbbVie5.79% -576.45% 13.39%
Johnson & Johnson 21.83%32.60%13.29%

AbbVie has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market.

70.2% of AbbVie shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

AbbVie presently has a consensus price target of $253.43, indicating a potential upside of 16.99%. Johnson & Johnson has a consensus price target of $253.04, indicating a potential upside of 10.81%. Given AbbVie's stronger consensus rating and higher probable upside, equities research analysts plainly believe AbbVie is more favorable than Johnson & Johnson.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AbbVie
0 Sell rating(s)
6 Hold rating(s)
16 Buy rating(s)
3 Strong Buy rating(s)
2.88
Johnson & Johnson
0 Sell rating(s)
7 Hold rating(s)
20 Buy rating(s)
0 Strong Buy rating(s)
2.74

Johnson & Johnson has higher revenue and earnings than AbbVie. Johnson & Johnson is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$61.16B6.26$4.23B$2.03106.71
Johnson & Johnson$94.19B5.84$26.80B$8.6526.40

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.2%. Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 2.3%. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson pays out 62.0% of its earnings in the form of a dividend. AbbVie has increased its dividend for 53 consecutive years and Johnson & Johnson has increased its dividend for 64 consecutive years.

In the previous week, Johnson & Johnson had 46 more articles in the media than AbbVie. MarketBeat recorded 108 mentions for Johnson & Johnson and 62 mentions for AbbVie. Johnson & Johnson's average media sentiment score of 1.36 beat AbbVie's score of 1.19 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AbbVie
49 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Johnson & Johnson
92 Very Positive mention(s)
8 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
3 Very Negative mention(s)
Positive

Summary

Johnson & Johnson beats AbbVie on 11 of the 20 factors compared between the two stocks.

How does Johnson & Johnson compare to Astrazeneca?

Johnson & Johnson (NYSE:JNJ) and Astrazeneca (NYSE:AZN) are related large-cap companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Johnson & Johnson has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

In the previous week, Johnson & Johnson had 100 more articles in the media than Astrazeneca. MarketBeat recorded 108 mentions for Johnson & Johnson and 8 mentions for Astrazeneca. Johnson & Johnson's average media sentiment score of 1.36 beat Astrazeneca's score of 0.85 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Johnson & Johnson
92 Very Positive mention(s)
8 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
3 Very Negative mention(s)
Positive
Astrazeneca
5 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Johnson & Johnson has a net margin of 21.83% compared to Astrazeneca's net margin of 17.19%. Johnson & Johnson's return on equity of 32.60% beat Astrazeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
Johnson & Johnson21.83% 32.60% 13.29%
Astrazeneca 17.19%30.86%12.68%

69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Johnson & Johnson presently has a consensus price target of $253.04, indicating a potential upside of 10.81%. Astrazeneca has a consensus price target of $205.33, indicating a potential upside of 17.42%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts clearly believe Astrazeneca is more favorable than Johnson & Johnson.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Johnson & Johnson
0 Sell rating(s)
7 Hold rating(s)
20 Buy rating(s)
0 Strong Buy rating(s)
2.74
Astrazeneca
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.85

Johnson & Johnson has higher revenue and earnings than Astrazeneca. Astrazeneca is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$94.19B5.84$26.80B$8.6526.40
Astrazeneca$58.74B4.62$10.23B$6.6626.26

Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 2.3%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.5%. Johnson & Johnson pays out 62.0% of its earnings in the form of a dividend. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has increased its dividend for 64 consecutive years.

Summary

Johnson & Johnson beats Astrazeneca on 16 of the 19 factors compared between the two stocks.

How does Johnson & Johnson compare to Berkshire Hathaway?

Johnson & Johnson (NYSE:JNJ) and Berkshire Hathaway (NYSE:BRK.B) are related large-cap companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 39.3% of Berkshire Hathaway shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by insiders. Comparatively, 6.1% of Berkshire Hathaway shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Johnson & Johnson has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, Berkshire Hathaway has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

Johnson & Johnson currently has a consensus price target of $253.04, suggesting a potential upside of 10.81%. Berkshire Hathaway has a consensus price target of $524.50, suggesting a potential upside of 7.33%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, equities analysts clearly believe Johnson & Johnson is more favorable than Berkshire Hathaway.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Johnson & Johnson
0 Sell rating(s)
7 Hold rating(s)
20 Buy rating(s)
0 Strong Buy rating(s)
2.74
Berkshire Hathaway
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Johnson & Johnson had 96 more articles in the media than Berkshire Hathaway. MarketBeat recorded 108 mentions for Johnson & Johnson and 12 mentions for Berkshire Hathaway. Johnson & Johnson's average media sentiment score of 1.36 beat Berkshire Hathaway's score of 0.32 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Johnson & Johnson
92 Very Positive mention(s)
8 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
3 Very Negative mention(s)
Positive
Berkshire Hathaway
3 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Johnson & Johnson has a net margin of 21.83% compared to Berkshire Hathaway's net margin of 19.31%. Johnson & Johnson's return on equity of 32.60% beat Berkshire Hathaway's return on equity.

Company Net Margins Return on Equity Return on Assets
Johnson & Johnson21.83% 32.60% 13.29%
Berkshire Hathaway 19.31%6.55%3.80%

Berkshire Hathaway has higher revenue and earnings than Johnson & Johnson. Berkshire Hathaway is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$94.19B5.84$26.80B$8.6526.40
Berkshire Hathaway$371.44B2.84$66.97B$33.5914.55

Summary

Johnson & Johnson beats Berkshire Hathaway on 11 of the 16 factors compared between the two stocks.

Get Johnson & Johnson News Delivered to You Automatically

Sign up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JNJ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JNJ vs. The Competition

Export
MetricJohnson & JohnsonLarge Cap Pharma IndustryMedical SectorNYSE Exchange
Market Cap$549.78B$302.55B$6.43B$23.21B
Dividend Yield2.35%2.85%2.68%4.06%
P/E Ratio26.4027.0424.7531.61
Price / Sales5.844.99530.01112.15
Price / Cash16.1812.9045.0724.44
Price / Book6.757.7210.804.68
Net Income$26.80B$11.61B$3.57B$1.08B
7 Day Performance-5.07%-3.12%0.73%-0.82%
1 Month Performance-0.37%-1.17%1.35%1.61%
1 Year Performance52.44%18.96%29.31%24.87%

Johnson & Johnson Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JNJ
Johnson & Johnson
4.63 of 5 stars		$228.37
0.0%		$253.04
+10.8%		+51.5%$549.78B$94.19B26.40138,200
MRNA
Moderna
1.2221 of 5 stars		$55.92
+7.3%		$36.60
-34.6%		+151.8%$21.92B$1.94BN/A4,700
NVAX
Novavax
1.7716 of 5 stars		$9.26
+0.5%		$12.13
+31.0%		+44.9%$1.53B$1.12BN/A1,990
ABBV
AbbVie
4.6632 of 5 stars		$221.72
+0.1%		$253.43
+14.3%		+16.9%$391.59B$61.16B109.1857,000
AZN
Astrazeneca
4.7031 of 5 stars		$178.88
+0.9%		$205.33
+14.8%		N/A$277.50B$58.74B26.8796,100

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:JNJ) was last updated on 6/20/2026 by MarketBeat.com Staff.
From Our Partners
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...
InvestPub | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Elon Is Quietly Doubling Down on This Bizarre Asset
Yahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...
Brownstone Research | Sponsoredtc pixel
An Elon Musk Fan's Warning About SPCX
Jon Najarian called Tesla in 2014 when legacy automakers dismissed it. Now he's warning investors to skip SPCX...
Banyan Hill Publishing | Sponsoredtc pixel